Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Claim 1 (currently amended): A method of inhibiting an unwanted angiogenic condition in a mammal in need thereof comprising administering to the mammal an effective amount of ~~an~~ a modified immunogen that causes an immune response against a molecule that induces angiogenesis in the mammal, wherein the immunogen comprises an angiogenesis associated receptor.

Claim 2 (currently amended): The method of claim 1, wherein the unwanted angiogenic condition [is] results from tumor growth, arthritis, macular degeneration, or psoriasis.

Claim 3-5 (cancelled).

Claim 6 (original): The method of claim 1 wherein the mammal is a human.

Claim 7 (original): The method of claim 1 wherein the immunogen is an antigen that is native to the mammal, and that is modified to improve immunogenecity.

Claim 8 (original): The method of claim 7 wherein the antigen is a haptenized antigen.

Claim 9 (original): The method of claim 7 wherein the antigen is conjugated to an immunogenic compound.

Claim 10 (original): The method of claim 7 wherein the antigen is combined with an adjuvant.

Claim 11 (withdrawn): The method of claim 1 wherein the immunogen is bound to a MHC Class I Restricted Antigen forming a complex not native to the mammal.

Claim 12 (withdrawn): The method of claim 1 wherein the immunogen is bound to a MHC Class II Restricted Antigen forming a complex not native to the mammal.

Claim 13-16 (cancelled).

Claim 17 (previously presented): The method of claim 1 wherein the immunogen is expressed on an antigen-presenting cell that is not native to the mammal.

Claim 18 (original): The method of claim17 wherein the antigen-presenting cell is a dendritic cell.

Claim 19 (cancelled).

Claim 20 (currently amended): The method of claim 1, wherein the molecule that induces angiogenesis is FLK-1, KDR, FLT-1, TIE-1, or TIE-2/Tek.

Claims 21-56 (cancelled).